Table 2. Baseline characteristics and clinical course in CMV-DNA+ patients with and without anti-CMV therapy (n = 12).
| Case | UC characteristics at baseline | CMV characteristics | UC clinical course after antivirus therapy | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAI score | Steroid use (mg/ 4w) | Steroid refractory/ dependent | Immunomodulator a use | CMV- Ag* | CMV-IHC** | CMV- DNA | CMV therapy | 5-ASA | Steroid | AZA | TAC | CyA | IFX | Outcome | |
| 1 | 5 | 975 | Dependent | AZA | 1 | 0 | 9,000 | Val GCV | → | ↘ | − | + | − | − | Remission |
| 2 | 12 | 845 | Dependent | 0 | 4 | 10,000 | GCV/ Foscarnet | → | ↘ | − | − | − | − | Remission | |
| 3 | 9 | 200 | Dependent | 0 | 4 | 13,400 | Val GCV | → | ↘ | − | − | − | − | Remission | |
| 4 | 12 | 880 | Refractory | 1 | 0 | 18,600 | GCV | → | ↘ | + | + | + | − | Remission | |
| 5 | 12 | 0 | 11 | 12 | 28,500 | Val GCV | → | ↑↘ | − | − | − | − | Remission | ||
| 6 | 10 | 1,200 | Dependent | 1 | 13 | 36,400 | GCV | → | ↘ | + | − | − | + | Surgery | |
| 7 | 8 | 0 | NA | 0 | 157 | - | → | - | − | − | − | − | Remission | ||
| 8 | 9 | 0 | 0 | 0 | 200 | - | → | ↑↘ | + | − | − | − | Remission | ||
| 9 | 10 | 260 | Refractory | 0 | 0 | 307 | - | → | ↑↘ | + | − | − | − | Remission | |
| 10 | 8 | 0 | 0 | 0 | 1,530 | - | → | ↑↘ | − | − | − | − | Remission | ||
| 11 | 6 | 0 | NA | 0 | 4,290 | - | → | ↑↘ | − | − | − | − | Remission | ||
| 12 | 6 | 80 | NA | 0 | 5,480 | - | → | ↑↘ | + | − | − | − | Remission | ||
aimmunomodulators include azathioprine, tacrolimus, and cyclosporine.
*number of positive cells,
**number of positive cells.
Arrows indicate changes in medication dose:“→”, no change in dose;“↑↘”, dose was increased then decreased;“↘”, dose was decreased. Abbreviations: NA, not applicable; AZA, azathioprine; Ag, antigenemia; IHC, immunohistochemistry; PCR, polymerase chain reaction; 5-ASA, 5-aminosalicylic acid; TAC, tacrolimus; CyA, cyclosporine; IFX, infliximab; ValGCV, valganciclovir; GCV, ganciclovir.